Sign in

Checkpoint inhibitor immunotherapy

2011

The FDA approves ipilimumab for melanoma, the first drug that releases a brake on the immune system to attack cancer.

The story

On March 25, 2011, the US Food and Drug Administration approved ipilimumab, sold as Yervoy by Bristol Myers Squibb, for advanced melanoma, a deadly skin cancer. It was the first checkpoint inhibitor, a drug that does not attack the tumor directly but takes the brakes off the immune system. T cells, immune cells that can kill cancer, carry a protein called CTLA-4 that switches them down; the antibody ipilimumab blocks it, and the T cells attack the tumor more strongly. In a 2010 trial of patients with metastatic melanoma, median survival was 10 months with ipilimumab, compared with 6.4 months for a comparison group.

The idea came from James Allison, who showed in the mid-1990s that blocking CTLA-4 made mice reject tumors. A small firm, Medarex, developed the antibody. Only a minority of patients responded, but some of them stayed alive for years, and about one in five were still alive three years after starting treatment, and in pooled data survival then leveled off, with some patients followed for close to ten years, something unusual in melanoma. It can cause serious immune side effects such as colitis. Soon after, drugs blocking a different checkpoint, PD-1, discovered by Tasuku Honjo, produced stronger results in more cancers. Allison and Honjo shared the 2018 Nobel Prize in Physiology or Medicine.

Why it mattered

  • PD-1 and PD-L1 drugs, such as pembrolizumab and nivolumab, followed and treat lung, kidney, bladder and other cancers.
  • Cancer immunotherapy became a fourth pillar of treatment alongside surgery, radiation and chemotherapy.
  • Combination treatments blocking two checkpoints were developed to raise the share of patients responding.
  • The 2018 Nobel Prize recognized the discovery, and pharmaceutical research shifted heavily toward immuno-oncology.

Drafted by AI (Claude) from the sources above and checked against them by AI; no historian has reviewed this page. Spot a mistake? Suggest a correction. How pages are made

Community notes

Loading notes…

Learn more ranked by votes

VideoSearch YouTube
checkpoint inhibitor immunotherapy explained
Search YouTube